Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals (NASDAQ:RYTM), sold 1,520 shares of common stock on July 29, 2025, at a price of $85.93, for a total value of $130,613. The transaction comes as the $5.6 billion market cap company maintains impressive gross profit margins of nearly 90% and has delivered a strong 76% return over the past year, according to InvestingPro data.
According to a Form 4 filing with the Securities and Exchange Commission, the sale was executed to cover withholding taxes related to the vesting of restricted stock units.
On July 26, 2025, Cramer also exercised options to acquire 3,125 shares of Rhythm Pharmaceuticals’ common stock, which had no price. These options stemmed from restricted stock units.
In other recent news, Rhythm Pharmaceuticals has been the focus of several investment firms following promising developments in its obesity treatment pipeline. Canaccord Genuity raised its price target for Rhythm Pharmaceuticals to $105, maintaining a Buy rating after attending the Endocrine Society’s Annual Meeting. BofA Securities also increased its price target to $109, citing positive Phase 2 topline data for bivamelagon, Rhythm’s next-generation oral MC4R agonist. Citizens JMP set an even higher price target of $130, following data from the Phase 3 TRANSCEND trial of setmelanotide and additional Phase 2 data for bivamelagon. Morgan Stanley (NYSE:MS) reiterated an Overweight rating with a $95 price target, noting significant BMI reductions in Phase 2 data for bivamelagon in hypothalamic obesity. Goldman Sachs resumed coverage with a Buy rating and a $97 price target, citing a potential $1.9 billion market opportunity in hypothalamic obesity. These developments highlight the growing interest and optimism among analysts regarding Rhythm Pharmaceuticals’ future prospects in the obesity treatment market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.